Hematein inhibits atherosclerosis by inhibition of reactive oxygen generation and NF-κB-dependent inflammatory mediators in hyperlipidemic mice

Journal of Cardiovascular Pharmacology

Volumn 42, Issue 2, 2003, Pages 287-295

  Choi, Jae Hoon ^a   Jeong, Tae Sook ^b   Kim, Dae Yong ^a   Kim, Young Myeong ^c   Na, Hee Jun ^c   Nam, Ki Hwan ^b   Lee, Sae Bom ^b   Kim, Hyoung Chin ^b   Oh, Sei Ryang ^b   Choi, Yang Kyu ^b   Bok, Song Hae ^b   Oh, Goo Taeg ^b  

^a Seoul National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Kangwon National University   (South Korea)

Author keywords

Anti inflammation; Antiatherogenesis; Hematein; NF B; Reactive oxygen species

Indexed keywords

ANTIINFLAMMATORY AGENT; CHOLESTEROL; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LIPID; LIPID PEROXIDE; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN RECEPTOR; NATURAL PRODUCT; NITRATE; NITRIC OXIDE SYNTHASE; NITRITE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA SINUS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL DIET; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DNA BINDING; HEMATEST; HYPERLIPIDEMIA; INFLAMMATION; MEDIATOR RELEASE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL;

ANIMALS; ARTERIOSCLEROSIS; CHOLESTEROL, DIETARY; FEMALE; HEMATOXYLIN; INFLAMMATION MEDIATORS; MACROPHAGES, PERITONEAL; MICE; NF-KAPPA B; REACTIVE OXYGEN SPECIES;

EID: 10744223286     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200308000-00019     Document Type: Article

References (32)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
2. Diaz MN, Frei B, Vita JA, et al. Anti-oxidants and atherosclerotic heart disease. N Engl J Med. 1997;337:408-416.
3. Thurberg BL, Collins T. The nuclear factor-κB/inhibitor of kappa B autoregulatory system and atherosclerosis. Curr Opin Lipidol. 1998;9: 387-396.
4. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of NF-κB and HIV-1. EMBO J. 1991;10:2247-2258.
5. Mihm S, Ennen J, Pessara U, et al. Inhibition of HIV-1 replication and NF-κB activity by cysteine and its derivatives. AIDS. 1991;5:497-503.
6. Islam KN, Devaraj S, Jialal I. α-Tocopherol enrichment of monocytes decreases agonist-induced adhesion to human endothelial cells. Circulation. 1998;98:2255-2261.
7. Buttery LD, Springall DR, Chester AH, et al. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest. 1996;75:77-85.
8. Wilcox JN, Subramanian RR, Sundell CL, et al. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol. 1997;17:2479-2488.
9. Luoma JS, Stralin P, Marklund SL, et al. Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1998;18: 157-167.
10. Wever RMF, Luscher TF, Cosentino R, et al. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation. 1998;97:108-112.
11. Detmers PA, Hernandez M, Mudgett J, et al. Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice. J Immunol. 2000;165:3430-3435.
12. Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA. 1990;87:1620-1624.
13. Lo AH, Liang YC, Lin-Shiau SY, et al. Carnosol, an antioxidant in rosemary, suppresses inducible nitric oxide synthase through down-regulating nuclear factor-kappaB in mouse macrophages. Carcinogenesis. 2002;23: 983-991.
14. Kang JS, Jeon YJ, Kim HM, et al. Inhibition of inducible nitric-oxide synthase expression by silymarin in lipopolysaccharide-stimulated macrophages. J Pharmacol Exp Ther. 2002;302:138-144.
15. Hong JJ, Jeong TS, Choi JH, et al. Hematein inhibits tumor necrosis factor-α-induced vascular cell adhesion molecule-1 and NF-κB-dependent gene expression in human vascular endothelial cells. Biochem Biophys Res Commun. 2001;281:1127-1133.
16. Oh GT, Choi JH, Hong JJ, et al. Dietary hematein ameliorates fatty streak lesions in the rabbit by the possible mechanism of reducing VCAM-1 and MCP-1 expression. Atherosclerosis. 2001;159:17-26.
17. Paigen B, Morrow A, Holmes PA, et al. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 1987;68:231-240.
18. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissue by thiobarbituric acid reaction. Anal Biochem. 1979;95:351-358.
19. Fridovich I. Superoxide radical and superoxide dismutases. Annu Rev Biochem. 1995;64:97-112.
20. Whitley M, Thamos D, Read M, et al. A striking similarity in the organization of the E-selectin and beta interferon gene promoters. Mol Cell Biol. 1994;14:6464-6475.
21. Pierce JW, Lenardo M, Baltimore D. Oligonucleotide that binds nuclear factor NF-kappa B acts as a lymphoid-specific and inducible enhancer element. Proc Natl Acad Sci USA. 1988;85:1482-1486.
22. Lowenstein CJ, Alley EW, Raval P, et al. Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon γ and lipopolysaccharide. Proc Natl Acad Sci U S A. 1993;90:9730-9734.
23. Morita K, Ihnken K, Buckberg GD, et al. Role of controlled cardiac reoxygenation in reducing nitric oxide production and cardiac oxidant damage in cyanotic infantile hearts. J Clin Invest. 1994;93:2658-2666.
24. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066-1071.
25. Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system. Annu Rev Immunol. 1994; 12:141-179.
26. Beutler B, Huffel CV. An evolutionary and functional approach to the TNF receptor/ligand family. Ann N Y Acad Sci. 1994;730:118-133.
27. Brand K, Eisele T, Kreusel U, et al. Dysregulation ofmonocytic nuclear factor-κB by oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol. 1997;17:1901-1909.
28. Brand K, Page S, Rogler G, et al. Activated transcription factor nuclear factor-kappaB is present in the atherosclerotic lesion. J Clin Invest. 1996; 97:1715-1722.
29. Ihrig M, Dangler CA, Fox JG. Mice lacking inducible nitric oxide synthase develop spontaneous hypercholesterolaemia and aortic atheromas. Atherosclerosis. 2001;156:103-107.
30. Kuhlencordt PJ, Chen J, Han F, et al. Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation. 2001;26;103: 3099-3104.
31. Behr-Roussel D, Rupin A, Simonet S, et al. Effect of chronic treatment with the inducible nitric oxide synthase inhibitor N-iminoethyl-L-lysine or with L-arginine on progression of coronary and aortic atherosclerosis in hypercholesterolemic rabbits. Circulation. 2000;102:1033-1038.
32. Beckman JS, Koppenol WH. Nitric oxide, superoxide and peroxynitrite: the good, the bad and the ugly. Am J Physiol. 1996;271:C1424-C1437.